RNACTIVE
RNActive is a biopharmaceutical company providing academic research and specialized in development for RNA-based medicines.
RNACTIVE
Industry:
Biotechnology Medical Pharmaceutical
Address:
Tübingen, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.curevac.com
Total Employee:
251+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Apache Global Site Tag
Similar Organizations
Pharmatech
Pharmatech is a pharmaceuticals company providing clinical research management and SMO services.
Official Site Inspections
http://www.curevac.com
- Host name: dedi3042.your-server.de
- IP address: 188.40.29.42
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "RNActive"
CureVac - Wikipedia
CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates …See details»
CureVac - LinkedIn
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In …See details»
CureVac Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 CureVac has 5 employees across 6 locations and €535.18 m in annual revenue in FY 2024. See insights on CureVac including office locations, competitors, revenue, financials, …See details»
CureVac N.V. (CVAC) Company Profile & Facts - Yahoo Finance
See the company profile for CureVac N.V. (CVAC) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
CureVac - Crunchbase Company Profile & Funding
CureVac develops messenger RNA (mRNA) technology for a variety of medical applications. The company focuses on creating innovative therapies aimed at …See details»
About Us - CureVac
With a single discovery, CureVac opened the world up to the potential of mRNA to treat diseases and create vaccines. Officially founded in 2000, CureVac is …See details»
CureVac Announces Financial Results for the Second Quarter and …
4 days ago CureVac N.V. (Nasdaq: CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today …See details»
Overview - CureVac
Aug 8, 2025 For the first time, through CureVac’s development activities this remarkable molecule started to reveal its huge potential in treating disease to …See details»
CureVac Initiates Strategic Restructuring to Align …
Jul 3, 2024 CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative …See details»
CureVac - Wir revolutionieren die mRNA für das Leben …
CureVac ist ein globales biopharmazeutisches Unternehmen mit über 20 Jahren Erfahrung in der Entwicklung der mRNA-Technologie für medizinische Zwecke.See details»
CureVac
Driving medical progress From day one, people have always been central to CureVac’s mission — after all, we are on a mission to use therapeutic mRNA to transform people’s lives. That’s …See details»
Curavac - Targeted Active Therapy for Autoimmune Diseases
CuraVac is a clinical-stage biotechnology company developing Targeted Active Therapy and Active Targeted Immunotherapies for autoimmune diseases.See details»
Curevac NV Company Profile - Overview - GlobalData
Curevac NV (Curevac) is a biopharmaceutical company that develops new transformative medicines based on messenger ribonucleic acid (mRNA). The company’s pipeline products …See details»
CureVac Company Profile | Management and Employees List
CureVac Profile and History CureVac (Nasdaq: CVAC) is a pioneering multinational biotechnology company founded in 2000 to advance messenger RNA (mRNA) technology for application in …See details»
CureVac N.V. (CVAC): History, Ownership, Mission, How It Works
Discover Curevac N.V.s mission and history. Learn how its ownership and business model support innovative vaccine development and revenue.See details»
CureVac Announces Financial Results for the First Quarter of 2025 …
Mar 31, 2025 As CureVac's manufacturing organization is now solely serving the R&D pipeline, following the change such costs are no longer recognized as cost of sales.See details»
CureVac Secures $740 Million Patent Settlement as BioNTech …
4 days ago CureVac is slated for acquisition by BioNTech in a deal valued at approximately $1.25 billion, coinciding with a patent litigation settlement where CureVac will receive $370 …See details»
Technology - CureVac
Through our proprietary mRNA technology we are able to directly give the body the information it needs to fight disease. Driven by passion for patients, we seek life-altering results for …See details»
CureVac Announces Resolution of Patent Litigation with …
Aug 8, 2025 CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human …See details»
GSK provides update on US settlement of CureVac/BioNTech …
Aug 8, 2025 CureVac will make an upfront settlement of $370 million to GSK GSK will receive a 1% royalty on future Pfizer / BioNTech US sales of influenza, COVID-19 and related …See details»